Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.
The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.
A user shared their experience with scalp micropigmentation (SMP) after one year. They discussed using Minoxidil, finasteride, and RU58841 as treatments for hair loss.
The user switched from an alcohol-based Minoxidil to a non-alcohol variant with oleanolic acid due to scalp dryness. They are concerned if the non-alcohol variant will be less effective for hair growth.
The post and conversation are about using RU58841 mixed with Minoxidil once a night for hair loss. The user experienced side effects from Finasteride and chose RU58841 instead.
Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.
Combining minoxidil, pyrilutamide, and copper peptide is questioned, with advice to apply them separately to avoid reactions. Finasteride and minoxidil are recommended for effectiveness.